Indevus gets approvable letter

Indevus got a preliminary FDA nod on Valstar, its bladder cancer therapy. The drug had been taken off the market in 2002 because of "impurities" in the original formula; since then, the company has revamped its process. In May, Indevus submitted a chemistry, manufacturing, and controls supplement to the agency.

The FDA's new approvable letter blesses the chemistry portion of the app and asks for more info about manufacturing. Company officials say they'll answer within two months, and that they expect to re-introduce VALSTAR late this year or early next. 

- check out the release

Related Articles:
Indevus in $120M deal to acquire Valera. Report
Indevus halts research on pagoclone for PE. Report

Suggested Articles

Merck KGaA has big plans for a site in Switzerland where it intends to knit together biologics development and manufacturing. 

Biocon’s key biosimilars plant in Bengaluru, India, has gotten mixed reviews from the FDA and has now received a Form 483 with five observations.

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?